Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Lalisang RI, Erdkamp FL, Rodenburg CJ, Knibbeler-van Rossum CT, Nortier JW, van Bochove A, Slee PH, Voest EE, Wils JA, Wals J, Loosveld OJ, Smals AE, Blijham GH, Tjan-Heijnen VC, Schouten HC. Lalisang RI, et al. Among authors: wils ja. Breast Cancer Res Treat. 2011 Jul;128(2):437-45. doi: 10.1007/s10549-011-1558-3. Epub 2011 May 17. Breast Cancer Res Treat. 2011. PMID: 21584666 Clinical Trial.
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
Hospers GA, Schaapveld M, Nortier JW, Wils J, van Bochove A, de Jong RS, Creemers GJ, Erjavec Z, de Gooyer DJ, Slee PH, Gerrits CJ, Smit JM, Mulder NH. Hospers GA, et al. Among authors: wils j. Ann Oncol. 2006 Mar;17(3):443-9. doi: 10.1093/annonc/mdj104. Ann Oncol. 2006. PMID: 16500914 Free article. Clinical Trial.
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group. Wils J, et al. Eur J Cancer. 2003 Feb;39(3):346-52. doi: 10.1016/s0959-8049(02)00662-7. Eur J Cancer. 2003. PMID: 12565987 Clinical Trial.
Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
Lalisang RI, Wils JA, Nortier HW, Burghouts JT, Hupperets PS, Erdkamp FL, Schouten HC, Blijham GH. Lalisang RI, et al. Among authors: wils ja. J Clin Oncol. 1997 Apr;15(4):1367-76. doi: 10.1200/JCO.1997.15.4.1367. J Clin Oncol. 1997. PMID: 9193328 Clinical Trial.
Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
Wagener DJ, Hoogenraad WJ, Rougier P, Lusinchi A, Taal BG, Veenhof CH, de Graeff A, Conroy T, Curran D, Sahmoud T, Wils J. Wagener DJ, et al. Among authors: wils j. Eur J Cancer. 1996 Jul;32A(8):1310-3. doi: 10.1016/0959-8049(96)00070-6. Eur J Cancer. 1996. PMID: 8869091 Free article. Clinical Trial.
212 results